Pneumococcal Vaccine Market Size, Share, Growth, Forecast 2030

Pneumococcal Vaccine Industry Prospective:

The global pneumococcal vaccine market size was worth around USD 5.4 billion in 2022 and is predicted to grow to around USD 7.5 billion by 2030 with a compound annual growth rate (CAGR) of roughly 4.2% between 2023 and 2030.    

Request Free Sample      

Pneumococcal Vaccine Market: Overview

Pneumococcal vaccinations are those that shield people from pneumococcal diseases. The bacterium Streptococcus pneumonia is responsible for the disease. Vaccines against pneumococci can shield people against diseases including sepsis, meningitis, and pneumonia. Vaccines may be divided into two categories: polysaccharide vaccines and conjugate vaccinations. The drug is administered by injecting it either into the muscle or just beneath the skin. Children and newborns should get conjugate vaccinations as part of a standard immunization schedule, according to the World Health Organization (WHO).

Key Insights

• As per the analysis shared by our research analyst, the global Pneumococcal Vaccine market is estimated to grow annually at a CAGR of around 4.2% over the forecast period (2023-2030).
• In terms of revenue, the global Pneumococcal Vaccine market size was valued at around USD 5.4 billion in 2022 and is projected to reach USD 7.5 billion, by 2030.
• The growing prevalence of pneumonia across the globe is expected to propel the pneumococcal vaccine market growth during the forecast period.
• Based on the vaccine type, the pneumococcal conjugate vaccine segment is expected to capture the largest market share over the forecast period.
• Based on the product type, the prevnar 13 segment is expected to grow at the highest CAGR over the forecast period.
• Based on region, North America is expected to dominate the market over the forecast period.

Pneumococcal Vaccine Market: Growth Drivers

The high burden of disease drives market expansion

Pneumococcal diseases, such as pneumonia, meningitis, and septicemia, have a considerable negative effect on public health, leading to morbidity & death, especially in susceptible groups including young children and the elderly. Pneumococcal vaccinations are in great demand as an efficient preventative strategy due to the high disease burden. For instance, according to UNICEF data, more children than any other infectious disease die through pneumonia each year, killing about 700,000 children under the age of five, or over 2,000 people each day. More than 200,000 infants are included. Nearly all of these fatalities might be avoided. Pneumonia affects more than 1,400 children worldwide per 100,000, or one child out of every 71, each year. The highest incidences are seen in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000 children). Therefore, the aforementioned stats are expected to drive the global pneumococcal vaccine market growth during the forecast period.

Pneumococcal Vaccine Market: Restraints

Issues related to the supply chain hamper the market growth

Vaccines are often referred to as liquid gold. Furthermore, they participate in illegal activities. For instance, there are multiple layers and obstacles between different supply chain levels. Each vaccination often goes through theft, counterfeiting, and sabotage, among other frequent behaviors. Furthermore, vendors replace defective vaccination vials with saline water rather than discarding them, which leads to the products being sold on the black market. Second, a significant barrier has been the lack of experts who can immunize several people at once. Furthermore, there are restrictions on the market's buffer capacity sector. The supply and supply chain restrictions prevent any demand that is 20% or higher from being satisfied. The market has seen ongoing difficulties as a result of these causes. Thus, this is expected to restrain the pneumococcal vaccine market growth during the forecast period.

Pneumococcal Vaccine Market: Opportunities

Growing awareness provides an attractive opportunity for market growth

To address pneumonia-related mortality, the WHO has established a task force and taken several additional coordinated actions with UNICEF. "Global Action for Pneumonia and Diarrhea" is the name of the program. The plan also addresses the three crucial areas of PROTECT, PREVENT, and TREAT. They dictate that children should be forced to nurse and get supplemental nutrition in the first dimension. Furthermore, under the PREVENT program, WHO mandates that vulnerable adults and children receive pneumococcal immunizations. Children and patients with diseases should take the appropriate drugs in the last component, which focuses on TREATMENT. The designation of November 12 as World Pneumonia Day also promotes awareness and stability. Thus, this is expected to offer a lucrative opportunity for the pneumococcal vaccine industry growth.

Pneumococcal Vaccine Market: Challenges

Emerging antibiotic resistance poses a challenge to market growth

The rise of pneumococcus strains that are resistant to antibiotics presents an important challenge. The significance of immunization for pneumococcal infections is increased by strains that are resistant to antibiotics. Vaccines must, however, keep up with changing patterns of resistance. Thus, acting as a major challenge to the market growth.  

Pneumococcal Vaccine Market: Segmentation

The global Pneumococcal Vaccine industry is segmented based on vaccine type, product type, distribution channel, and region.

Based on the vaccine type, the global market is bifurcated into pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine. The pneumococcal conjugate vaccine segment is expected to capture the largest market share over the forecast period. These vaccinations can immunize newborns and kids between the ages of 6 weeks and 5 years old against invasive infections including pneumonia and acute otitis media. Due to the increased acceptance and usage of the vaccine among the population, as many people are vulnerable to pneumonia, including children under the age of five and individuals over the age of fifty, the PCV vaccine category is anticipated to have the largest market share. As a result, it makes up the greatest portion of the market for pneumonia vaccinations globally.

Based on the product type, the pneumococcal vaccine industry  is bifurcated into prevnar 13, synflorix and pneumovax 23. The prevnar 13 segment is expected to grow at the highest CAGR over the forecast period. Prevnar 13 is one of the vaccine kinds that the WHO recommends the most, and most nations utilize it during national immunization campaigns. Adults over the age of 50 are encouraged to use it. Thus, this is expected to drive the market growth during the forecast period.

Based on the distribution channel, the pneumococcal vaccine industry  is bifurcated into distribution partner companies, non-governmental organizations (NGOs), and government authorities.

Pneumococcal Vaccine Market: Report Scope

Pneumococcal Vaccine Market: Regional Analysis

North America is expected to dominate the market growth over the forecast period

North America is expected to dominate the global pneumococcal vaccine market during the forecast period due to elements like the existence of major companies and well-established healthcare infrastructure, which are the main elements responsible for its significant market share. Additionally, a rise in pneumonia incidence in the study region and increased investment in the development of pneumococcal vaccines are anticipated to support market expansion. Pneumococcal pneumonia causes over 150,000 hospital admissions annually in the United States, according to data from the National Foundation for Infectious Diseases, updated in March 2022. Market expansion is anticipated as a result of the high frequency of pneumococcal infection in the area. Additionally, according to the CDC's January 2023 report, 24.0% of individuals in the United States over the age of 18 had gotten a pneumococcal immunization in 2021. As a result, an increase in pneumonia incidence is anticipated to fuel demand for pneumococcal vaccinations in the analyzed area and support market expansion throughout the forecast period.

On the other hand, the Asia Pacific is expected to grow at the highest CAGR over the forecast period. The market growth in the region is attributed to the growing government initiatives. Several countries in the Asia Pacific have adopted national immunization programs that include pneumococcal vaccination. These programs are often supported by international organizations and aim to increase vaccine coverage rates, particularly among infants. Moreover, pneumococcal vaccinations have been made available in several nations throughout the region, frequently as a standard component of children's immunization regimens. The prevalence of pneumococcal diseases in children has significantly decreased with the introduction of pneumococcal conjugate vaccinations (PCVs). Thus, this is expected to drive market growth in the region over the forecast period.

Pneumococcal Vaccine Market: Competitive Analysis

The global Pneumococcal Vaccine market is dominated by players like:

• Walvax Biotechnology Co. Ltd.
• Sk Bioscience
• Panacea Biotec Limited
• Shenzhen Kangtai Biological Products Co. Ltd.
• (Beijing Minhai Biotechnology Corporation Limited)
• Serum Institute of India Pvt. Ltd.
• Merck & Co. Inc.
• Pfizer Inc.
• Lg Chem Ltd.
• Pnuvax Incorporated
• Glaxosmithkline Plc.

The global Pneumococcal Vaccine market is segmented as follows:

By Vaccine Type

• Pneumococcal Conjugate Vaccine
• Pneumococcal Polysaccharide Vaccine

By Product Type

• Prevnar 13
• Synflorix
• Pneumovax 23

By Distribution Channel

• Distribution Partner Companies
• Non-governmental Organizations (NGO)
• Government Authorities

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa